Confronto
Dulaglutide vs. Maridebart Cafraglutide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
923950-08-7
nessun dato
Peso molecolare
59670 g/mol
nessun dato
Emivita
110 h
nessun dato
Sequenza
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-Fcnessun dato
Meccanismo d'azione
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
5
1
di cui sull'uomo
5
1
Effetti registrati
3
2
Contraddizioni aperte
1
0
Eventi avversi documentati
2
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Dulaglutide and Maridebart Cafraglutide?
- Dulaglutide is classified as "Metabolico", while Maridebart Cafraglutide is classified as "Metabolico". Dulaglutide: GLP-1 receptor agonist designed as a fusion protein of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc fragment. FDA-approved 2014 (Trulicity) for type 2 diabetes; EMA approval 2014. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Dulaglutide or Maridebart Cafraglutide?
- The highest available evidence level is "RCT sull'uomo" for Dulaglutide and "RCT sull'uomo" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Dulaglutide and Maridebart Cafraglutide in Germany and the United States?
- Germania: Dulaglutide — Su prescrizione, Maridebart Cafraglutide — Non approvato. Stati Uniti: Dulaglutide — Su prescrizione, Maridebart Cafraglutide — Non approvato. These are factual summaries with source and review date on the individual pages.